Jump to content

OPPORTUNITY: Previous cell therapy recipients


Recommended Posts



Research Opportunity: Providing The Patient Perspective on Cellular Therapies for Non-Small Cell Lung Cancer (NSCLC)

GlaxoSmithKline (GSK) wishes to understand the perspective of advanced-stage NSCLC patients who have received any cell-based therapies (such as CAR-T or TCR therapies).  They are specifically looking to speak with Patients who have:

·      Received any cell-based therapies in the last 24 months for metastatic NSCLC

·      Have had removal of blood components (specifically T-cells) through a process called apheresis, received lympho-depletion therapy (conditioning therapy with chemotherapy or other regimens), waited for infusion of the removed cells, and have received the infusion for these cell-based therapies

This research will consist of completing a short pre-interview worksheet and then participating in a brief, 45-minute web-assisted telephone call.

The research discussions will be scheduled to take place over the phone/WebEx in the month of October, 2018 based on availability.  For your time and valuable opinions, you may be compensated if you qualify.  Please contact Prani Paka at prani.8.paka@gsk.com for more information.




Link to comment
Share on other sites

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.